Department of Pharmacology, Pharmacovigilance unit/ Research and Development Division, Dhulikhel Hospital, Kathmandu University Hospital, Kathmandu University School of Medical Sciences, Dhulikhel, Kavre, Nepal.
Department of Pharmacology, Dhulikhel Hospital, Kathmandu University Hospital, Kathmandu University School of Medical Sciences, Dhulikhel, Kavre, Nepal.
Kathmandu Univ Med J (KUMJ). 2021 Apr-Jun;19(74):260-264.
Background Osteoarthritis (OA) is the most common chronic rheumatic disease. The prevalence of OA is skyrocketing with time. Providing a proper treatment regimen for OA is also growing as a major public health challenge. Conventional pharmacological treatments are mainly for alleviating pain and have some severe adverse effects. Diacerein is a new oral anti-inflammatory drug especially developed for the management of OA having only mild to moderate adverse effects. However, the evidence of efficacy and safety of Diacerein in OA is not well documented and yet to be explored. Objective To compare the efficacy and safety of Diacerein in knee OA with conventional nonsteroidal anti-inflammatory drugs (NSAIDs). Method A comparative study was conducted among knee OA patients attending OutPatient Orthopedic department in Dhulikhel Hospital, Nepal from December 2019 to September 2020, using self-structured and standard questionnaire. The patients were randomized to receive either a conventional standard treatment (Treatment Group I: NSAIDs) or alternative treatment regimen (Treatment Group II: NSAIDS+ Diacerein). Patients were followed-up after two months and data were analyzed using SPSS 21.0. Result Among 72 patients enrolled in this study, majority (44.44%) were between 51-60 years of age in which 81.94% of the patients were female. Post treatment data was collected from 15 participants. The mean KOOS-PS score of the participants in Treatment Group I decreased from 35.56 ± 14.33 to 35.14 ± 12.65 while that of the Treatment Group II participants reduced from 63.31 ± 12.08 to 49.99 ± 13.10 in two months. Similarly, the mean WOMAC score decreased from 46.87 ± 17.80 to 34.37 ± 16.83 in Treatment Group I and from 54.23 ± 14.66 to 46.22 ± 12.16 in Treatment Group II. The mean Lysholm score in Treatment Group I increased from 55.57 ± 8.16 to 60.86 ± 15.01 and in Treatment Group II, it increased from 46.62 ± 13.01 to 60.25 ± 17.598. Conclusion Diacerein treatment group had better functional outcome compared to the patients in the treatment group with conventionally used drugs. Also, the adverse effects faced by the patients were minor. The current study are suggestive of better efficacy and safety of Diacerein compared to other drugs.
骨关节炎（OA）是最常见的慢性风湿性疾病。OA 的患病率随着时间的推移呈飙升趋势。为 OA 提供适当的治疗方案也成为一个主要的公共卫生挑战。传统的药理学治疗主要用于缓解疼痛，并且具有一些严重的副作用。双醋瑞因是一种新的口服抗炎药，专门用于治疗 OA，只有轻度至中度的副作用。然而，双醋瑞因在 OA 中的疗效和安全性证据尚不清楚，有待探索。目的：比较双醋瑞因与传统非甾体抗炎药（NSAIDs）治疗膝骨关节炎的疗效和安全性。方法：对 2019 年 12 月至 2020 年 9 月在尼泊尔 Dhulikhel 医院骨科门诊就诊的膝骨关节炎患者进行了一项比较研究，使用了自构和标准问卷。患者被随机分配接受常规标准治疗（治疗组 I：NSAIDs）或替代治疗方案（治疗组 II：NSAIDs+双醋瑞因）。治疗后两个月进行随访，并使用 SPSS 21.0 进行数据分析。结果：在这项研究中，共有 72 名患者入组，其中大多数（44.44%）年龄在 51-60 岁之间，其中 81.94%的患者为女性。从治疗组 I 中收集了 15 名参与者的治疗后数据。治疗组 I 参与者的 KOOS-PS 评分从 35.56 ± 14.33 降至 35.14 ± 12.65，而治疗组 II 参与者的评分从 63.31 ± 12.08 降至 49.99 ± 13.10，均在两个月内下降。同样，WOMAC 评分从治疗组 I 的 46.87 ± 17.80 降至 34.37 ± 16.83，从治疗组 II 的 54.23 ± 14.66 降至 46.22 ± 12.16。治疗组 I 的 Lysholm 评分从 55.57 ± 8.16 增加到 60.86 ± 15.01，治疗组 II 的 Lysholm 评分从 46.62 ± 13.01 增加到 60.25 ± 17.598。结论：与使用传统药物的治疗组相比，双醋瑞因治疗组的功能结果更好。此外，患者所面临的不良反应较小。目前的研究表明，与其他药物相比，双醋瑞因具有更好的疗效和安全性。
